Statin with SGLT2i for ischemic heart disease
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests if taking a statin along with an SGLT2 inhibitor (a diabetes drug that also helps the heart) works better for people with heart disease caused by blocked arteries. The goal is to improve heart function with this combination therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ischemic heart disease (heart problems from blocked arteries) that has led to heart failure.
- Your doctor has recommended or you are already taking a statin and an SGLT2 inhibitor.
- You do not have serious liver or kidney problems.
- You do not have a fungal infection or a bleeding disorder.
- You are not taking any medications that interfere with SGLT2 inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving an SGLT2 inhibitor (a diabetes medicine that may also protect the heart) early after a heart attack can help shield the heart from damage. It is for people having a first-time STEMI heart attack who have adequate kidney function and stable blood pressure.
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
This study looks at whether a type of diabetes medicine called SGLT2 inhibitors (also known as flozins) can help protect the heart and kidneys in people with both heart failure with preserved pumping function and moderate chronic kidney disease, with or without diabetes.
This study tests whether a diabetes medication called SGLT2 inhibitors can slow the buildup of plaque in heart arteries. Researchers will use special CT scans to track changes in your coronary arteries over time.
This study looks at how starting an SGLT2 inhibitor (a diabetes medicine) around the time of a heart attack affects heart outcomes and heart muscle changes over time. It may help you and your care team understand whether this timing is beneficial after a PCI procedure.
Hear when a new 2 Drugs Are Statin and SGLT2i trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.